Trial reportScientific reports2026
Dexmedetomidine for sedation during noninvasive ventilation in COVID-19 patients from the Helmet-COVID randomized clinical trial post-hoc analysis.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexmedetomidine may be used in patients managed by noninvasive ventilation (NIV), but its associations with intubation, mortality and health-related quality of life (HRQoL) are unclear. Thus, we aimed to assess the use of dexmedetomidine in patients with COVID-19-induced acute hypoxemic respiratory failure requiring NIV and its associations with the 28-day intubation rate, 28- and 180-day mortality rate, and HRQoL. This post-hoc study of the Helmet-COVID trial analyzed data from NIV-managed patients who did and did not receive dexmedetomidine and assessed the association of dexmedetomidine with clinical outcomes. We evaluated HRQoL on day 180 using EuroQoL-5D-5L index values and the EQ visual analog scale (EQ-VAS). Non-survivors were assigned a value of 0 on the EQ-5D-5L and EQ-VAS. We used a generalized linear mixed model adjusted for the enrollment center and other baseline covariables. Of 290 patients managed with NIV, 107 (36.8%) were treated with dexmedetomidine. The median highest daily dose was 0.6 mcg/kg/h (interquartile range [IQR] 0.4, 0.9) for a median of 2.5 days (IQR: 1, 5). Baseline demographics and severity of respiratory failure, including the PaO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.